NCT03488693进行中（未招募）3 期
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,138
- 试验地点
- 760
- 主要终点
- compare the breast cancer recurrence-free interval (BCRFI) between patients that received regional RT or not
研究概览
简要总结
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
详细描述
Women with node positive breast cancer normally will receive endocrine therapy and some may receive chemotherapy to help prevent the cancer from coming back. Many women will also receive radiotherapy to the whole breast/chest area and the surrounding lymph glands (called regional radiotherapy). No one really knows whether patients with low risk breast cancer need to receive regional radiotherapy. Some women may be getting regional radiotherapy who do not need it. These women may be exposed to the side effects of their treatment without benefit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients must be women with newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases, staged as per site standard of care.
- •Patients must have been treated by BCS or mastectomy with clear margins of excision. Post-mastectomy positive margins for invasive disease and/or DCIS is not allowed. Multifocal disease (i.e. the presence of two or more foci or breast cancer within the same breast quadrant) and multicentric disease (i.e. the presence of two or more foci of breast cancer in different quadrants of the same breast) are allowed.
- •Patients with T3N0 disease are eligible.
- •Patients with disease limited to nodal micrometastases are eligible
- •Patients with nodal macrometastases (>2mm) treated by axillary dissection must have 1-3 positive axillary nodes (macrometastases, > 2 mm).
- •Patients treated by mastectomy and SLNB alone must have only 1-2 positive axillary nodes (macrometastases, > 2 mm).
- •Patients must be ER ≥ 1% and HER2 negative on local testing
- •Patients must have an Oncotype DX recurrence score ≤25 obtained from testing of breast tumour tissue from a core biopsy or from the surgical specimen.
- •Patient must consent to provision of, and investigator(s) must agree to submit to the CCTG Central Tumour Bank, a representative formalin fixed paraffin block of tumour tissue in order that the specific correlative marker assays described in the protocol may be conducted
- •Patient must consent to provision of samples of blood in order that the specific correlative marker assays described in the protocol may be conducted.
- •Patients must have had endocrine therapy initiated or planned for ≥ 5 years. Premenopausal women will receive ovarian ablation plus aromatase inhibitor therapy or tamoxifen if adjuvant chemotherapy was not administered. For all patients, endocrine therapy can be given concurrently or following RT.
- •Patients may or may not have had adjuvant chemotherapy.
- •RT must commence within 16 weeks of definitive surgery if the patient is not treated with chemotherapy. If adjuvant chemotherapy is given, RT must begin within 12 weeks after the last dose. (Note: adjuvant chemotherapy may be ongoing at the time of randomization). Definitive surgery is defined as the last breast cancer-related surgery.
- •Patient's ECOG performance status must be 0, 1 or
- •Patient's age must be ≥ 35 years.
- •For the first 736 eligible English or French-speaking subjects who have agreed to optional questionnaire completion: Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life, health utilities and lost productivity questionnaires in either English or French (note: enrollment completed 2022Aug02)
- •Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements
- •Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
- •In accordance with CCTG policy, protocol treatment is to begin within 6 weeks of patient randomization.
- •Women of childbearing potential must have agreed to use an effective contraceptive method. A woman is considered to be of "childbearing potential" if she has had menses at any time in the preceding 12 consecutive months.
排除标准
- •Patients with nodal disease limited to isolated tumour cells (pN0i+ < 0.2 mm).
- •Patients with pT3N1 and pT4 disease (Note: patients with T3N0 are eligible).
- •Any prior history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy. (Patients with synchronous or previous ipsilateral LCIS are eligible.)
- •Synchronous or previous contralateral invasive breast cancer. (Patients with contralateral DCIS are eligible unless previously treated with radiation.)
- •History of non-breast malignancies except adequately treated non-melanoma skin cancers, in situ cancers treated by local excision or other cancers curatively treated with no evidence of disease for ≥ 5 years.
- •Patients who are pregnant.
- •Patients that have had prior ipsilateral chestwall/thoracic radiation.
- •Patients treated with chemo or endocrine therapy administered in the neoadjuvant setting for breast cancer. Endocrine therapy exposure 12 weeks or less prior to surgery is permitted.
- •Patients with serious non-malignant disease (e.g. cardiovascular, scleroderma etc.) which would preclude RT.
- •Patients with any serious active or co-morbid medical conditions, laboratory abnormality, psychiatric illness, active or uncontrolled infections, or serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator's decision).
研究组 & 干预措施
Regional Radiotherapy
Active Comparator
A. WBI plus RT to the regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following BCS or; B. RT to the chestwall and regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following mastectomy
干预措施: Radiation (Radiation)
No Regional Radiotherapy
Active Comparator
A. Whole Breast Irradiation (WBI) following BCS or; B. No Radiotherapy (RT) following mastectomy
干预措施: Radiation (Radiation)
No Regional Radiotherapy
Active Comparator
A. Whole Breast Irradiation (WBI) following BCS or; B. No Radiotherapy (RT) following mastectomy
干预措施: No Radiation (Other)
结局指标
主要结局
compare the breast cancer recurrence-free interval (BCRFI) between patients that received regional RT or not
时间窗: 9.5 years
Defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to BC.
次要结局
- Compare the invasive disease-free survival between patients that received regional RT or not.(9.5 years)
- Compare arm volume and mobility measurements between patients that received regional RT or not(9.5 years)
- Compare the breast cancer mortality between patients that received regional RT or not.(9.5 years)
- Number and severity of adverse events using the current CTCAE version 4(9.5 years)
- Compare the cost-effectiveness between patients that received regional RT or not(9.5 years)
- Compare the overall survival (OS) between patients that received regional RT or not(9.5 years)
- Compare the locoregional recurrence-free interval (LRRFI) between patients that received regional RT or not.(9.5 years)
- Compare the distant recurrence-free interval (DRFI) between patients that received regional RT or not.(9.5 years)
- Compare patient-reported outcomes (PROs) and the quality of life (QOL) between patients that received regional RT or not(9.5 years)
- Compare the quality of life (QOL) between patients that received regional RT or not(9.5 years)
研究者
研究点 (760)
Loading locations...
相似试验
已完成
不适用
Assessing Impact of Loco-regional Treatment on Survival in Metastatic Breast Cancer at PresentationCancer of the BreastNCT00193778Tata Memorial Hospital350
已完成
1 期
A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast CancerBreast CancerNCT00581256University of Michigan Rogel Cancer Center54
进行中（未招募）
不适用
Randomized Study of Elective Regional Lymph Node Irradiation in N1 Breast CancerBreast NeoplasmNCT03269981Samsung Medical Center827
Unknown
不适用
A Randomized Study of Primary Tumor Radiotherapy for Patients With Stage Ⅳ NSCLCRadiotherapyNonsmall Cell Lung Cancer, Stage IVNCT04654520Guizhou Medical University290
Unknown
3 期
Resource-sparing Post-mastectomy Radiotherapy in Breast CancerBreast CancerNCT01452672International Atomic Energy Agency600